|
1
|
Silverman LB, Gelber RD, Dalton VK,
Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y,
Schorin MA, et al: Improved outcome for children with acute
lymphoblastic leukemia: Results of Dana-Farber consortium protocol
91-01. Blood. 97:1211–1218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conter V, Aricó M, Valsecchi MG, Rizzari
C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A,
Rondelli R, et al: Intensive BFM chemotherapy for childhood ALL:
Interim analysis of the AIEOP-ALL 91 study. Associazione Italiana
Ematologia Oncologia Pediatrica. Haematologica. 83:791–799.
1998.PubMed/NCBI
|
|
3
|
Gaynon PS, Steinherz PG, Bleyer WA, Ablin
AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF,
Reaman GH, et al: Improved therapy for children with acute
lymphoblastic leukemia and unfavorable presenting features: A
follow-up report of the Childrens cancer group study CCG-106. J
Clin Oncol. 11:2234–2242. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arico M, Valsecchi MG, Conter V, Rizzari
C, Pession A, Messina C, Barisone E, Poggi V, De Rossi G, Locatelli
F, et al: Improved out-come in high-risk childhood acute
lymphoblastic leukemia defined by prednisone-poor response treated
with double Berlin-Frankfurt-Muenster protocol II. Blood.
100:420–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin YH and Yang-Yen HF: The
osteopontin-CD44 survival signal involves activation of the
phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem.
276:46024–46030. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dick JE, Bhatia M, Gan O, Kapp U and Wang
JC: Assay of human stem cells by repopulation of NOD/SCID mice.
Stem Cells. 15 (Suppl 1):S199–S207. 1997. View Article : Google Scholar
|
|
7
|
Wiseman DH: Donor cell leukemia: A review.
Biol Blood Marrow Transplant. 17:771–789. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Juarez J, Bradstock KF, Gottlieb DJ and
Bendall LJ: Effects of inhibitors of the chemokine receptor CXCR4
on acute lymphoblastic leukemia cells in vitro. Leukemia.
17:1294–1300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Z, Wu D, Lin S and Li P: CD34 and
CD38 are prognostic biomarkers for acute B lymphoblastic leukemia.
Biomark Res. 4:232016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McCarthy DJ, Chen Y and Smyth GK:
Differential expression analysis of multifactor RNA-Seq experiments
with respect to biological variation. Nucleic Acids Res.
40:4288–4297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Feng Z, Wang X, Wang X and Zhang
X: DEGseq: An R package for identifying differentially expressed
genes from RNA-seq data. Bioinformatics. 26:136–138. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisterer W, Bechter O, Hilbe W, van Driel
M, Lokhorst HM, Thaler J, Bloem AC, Günthert U and Stauder R: CD44
isoforms are differentially regulated in plasma cell dyscrasias and
CD44v9 represents a new independent prognostic parameter in
multiple myeloma. Leuk Res. 25:1051–1057. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niitsu N and Iijima K: High serum soluble
CD44 is correlated with a poor outcome of aggressive non-Hodgkin's
lymphoma. Leuk Res. 26:241–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aruffo A, Stamenkovic I, Melnick M,
Underhill CB and Seed B: CD44 is the principal cell surface
receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bourguignon LY, Zhu H, Shao L, Zhu D and
Chen YW: Rho-kinase (ROK) promotes CD44v3, 8–10-ankyrin interaction
and tumor cell migration in metastatic breast cancer cells. Cell
Motil Cytoskeleton. 43:269–287. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khaldoyanidi SK, Goncharova V, Mueller B
and Schraufstatter IU: Hyaluronan in the healthy and malignant
hematopoietic microenvironment. Adv Cancer Res. 123:149–189. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuhn NZ and Tuan RS: Regulation of
stemness and stem cell niche of mesenchy-mal stem cells:
Implications in tumorigenesis and metastasis. J Cell Physiol.
222:268–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Rhenen A, Moshaver B, Kelder A, Feller
N, Nieuwint AW, Zweegman S, Ossenkoppele GJ and Schuurhuis GJ:
Aberrant marker expression patterns on the CD34+CD38-stem cell
compartment in acute myeloid leukemia allows to distinguish the
malignant from the normal stem cell compartment both at diagnosis
and in remission. Leukemia. 21:1700–1707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang B, Ho YW, Huang Q, Maeda T, Lin A,
Lee SU, Hair A, Holyoake TL, Huettner C and Bhatia R: Altered
microenvironmental regulation of leukemic and normal stem cells in
chronic myelogenous leukemia. Cancer Cell. 21:577–592. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maksym RB, Tarnowski M, Grymula K,
Tarnowska J, Wysoczynski M, Liu R, Czerny B, Ratajczak J, Kucia M
and Ratajczak MZ: The role of stromal-derived factor-1-CXCR7 axis
in development and cancer. Eur J Pharmacol. 625:31–40. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsiftsoglou AS, Bonovolias ID and
Tsiftsoglou SA: Multilevel targeting of hematopoietic stem cell
self-renewal, differentiation and apoptosis for leukemia therapy.
Pharmacol Ther. 122:264–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fouillard L, Francois S, Bouchet S,
Bensidhoum M, Elm'selmi A and Chapel A: Innovative cell therapy in
the treatment of serious adverse events related to both
chemo-radiotherapy protocol and acute myeloid leukemia syndrome:
The infusion of mesenchymal stem cells post-treatment reduces
hematopoietic toxicity and promotes hematopoietic reconstitution.
Curr Pharm Biotechnol. 14:842–848. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lapalombella R: Interleukin-6 in CLL:
Accelerator or brake? Blood. 126:697–698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jafarzadeh N, Safari Z, Pornour M,
Amirizadeh N, Forouzandeh Moghadam M and Sadeghizadeh M: Alteration
of cellular and immune-related properties of bone marrow
mesenchymal stem cells and macrophages by K562 chronic myeloid
leukemia cell derived exosomes. J Cell Physiol. 234:3697–3710.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Tu H, Yang Y, Wan Q, Fang L, Wu Q
and Li J: High IL-7 levels in the bone marrow microenvironment
mediate imatinib resistance and predict disease progression in
chronic myeloid leukemia. Int J Hematol. 104:358–367. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Supper E, Tahir S, Imai T, Inoue J and
Minato N: Modification of gene expression, proliferation, and
function of OP9 Stroma cells by Bcr-Abl-expressing leukemia cells.
PLoS One. 10:e01340262015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wetzler M, Talpaz M, Lowe DG, Baiocchi G,
Gutterman JU and Kurzrock R: Constitutive expression of leukemia
inhibitory factor RNA by human bone marrow stromal cells and
modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol.
19:347–351. 1991.PubMed/NCBI
|
|
29
|
Chakravarti S, Stallings RL, Sundarraj N,
Cornuet PK and Hassell JR: Primary structure of human lumican
(Keratan Sulfate Proteoglycan) and localization of the gene (LUM)
to chromosome 12q21.3-q22. Genomics. 27:481–488. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jeanne A, Untereiner V, Perreau C, Proult
I, Gobinet C, Boulagnon-Rombi C, Terryn C, Martiny L, Brézillon S
and Dedieu S: Lumican delays melanoma growth in mice and drives
tumor molecular assembly as well as response to matrix-targeted
TAX2 therapeutic peptide. Sci Rep. 7:77002017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karamanou K, Franchi M, Piperigkou Z,
Perreau C, Maquart FX, Vynios DH and Brézillon S: Lumican
effectively regulates the estrogen receptors-associated functional
properties of breast cancer cells, expression of matrix effectors
and epithelial-to-mesenchymal transition. Sci Rep. 7:451382017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Wit M, Carvalho B, Delis-van Diemen PM,
van Alphen C, Beliën JAM, Meijer GA and Fijneman RJA: Lumican and
versican protein expression are associated with colorectal
adenoma-to-carcinoma progression. PLoS One. 12:e01747682017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Naito Z, Ishiwata T, Kurban G, Teduka K,
Kawamoto Y, Kawahara K and Sugisaki Y: Expression and accumulation
of lumican protein in uterine cervical cancer cells at the
periphery of cancer nests. Int J Oncol. 20:943–948. 2002.PubMed/NCBI
|
|
34
|
Li X, Kang Y, Roife D, Lee Y, Pratt M,
Perez MR, Dai B, Koay EJ and Fleming JB: Prolonged exposure to
extracellular lumican restrains pancreatic adenocarcinoma growth.
Oncogene. 36:5432–5438. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brézillon S, Venteo L, Ramont L, D'Onofrio
MF, Perreau C, Pluot M, Maquart FX and Wegrowski Y: Expression of
lumican, a small leucine-rich proteoglycan with antitumour
activity, in human malignant melanoma. Clin Exp Dermatol.
32:405–416. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vuillermoz B, Khoruzhenko A, D'Onofrio MF,
Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX and
Wegrowski Y: The small leucine-rich proteoglycan lumican inhibits
melanoma progression. Exp Cell Res. 296:294–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zéltz C, Brézillon S, Käpylä J, Eble JA,
Bobichon H, Terryn C, Perreau C, Franz CM, Heino J, Maquart FX and
Wegrowski Y: Lumican inhibits cell migration through α2β1 integrin.
Exp Cell Res. 316:2922–2931. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brézillon S, Radwanska A, Zeltz C,
Malkowski A, Ploton D, Bobichon H, Perreau C, Malicka-Blaszkiewicz
M, Maquart FX and Wegrowski Y: Lumican core protein inhibits
melanoma cell migration via alterations of focal adhesion
complexes. Cancer Lett. 283:92–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li X, Truty MA, Kang Y, Chopin-Laly X,
Zhang R, Roife D, Chatterjee D, Lin E, Thomas RM, Wang H, et al:
Extracellular lumican inhibits pancreatic cancer cell growth and is
associated with prolonged survival after surgery. Clin Cancer Res.
20:6529–6540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Q, Villeneuve G and Wang Z: Control
of epidermal growth factor receptor endocytosis by receptor
dimerization, rather than receptor kinase activation. EMBO Rep.
6:942–948. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Balakrishnan S, Mukherjee S, Das S, Bhat
FA, Raja Singh P, Patra CR and Arunakaran J: Gold
nanoparticles-conjugated quercetin induces apoptosis via inhibition
of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines
(MCF-7 and MDA-MB-231). Cell Biochem Funct. 35:217–231. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Niewiarowska J, Brézillon S,
Sacewicz-Hofman I, Bednarek R, Maquart FX, Malinowski M, Wiktorska
M, Wegrowski Y and Cierniewski CS: Lumican inhibits angiogenesis by
interfering with α2β1 receptor activity and downregulating MMP-14
expression. Thromb Res. 128:452–457. 2011. View Article : Google Scholar : PubMed/NCBI
|
